Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patientâ€™s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
11/09/26	US$1.720	+1.18%	393,555
10/09/26	US$1.700	+1.19%	9,491
09/09/26	US$1.680	0.00%	29,603
08/09/26	US$1.680	+1.20%	31,191
04/09/26	US$1.660	-2.35%	63,178

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.720USD

Average target price

26.00USD

Spread / Average Target

+1,411.63%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq 21:00:00 11/09/2026 BST			5-day change	1st Jan Change
1.720 ^USD	+1.18%		+3.61%	-5.49%

09-10	Alzamend Neuro, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2026	CI
08-20	Alzamend Neuro Reports Resting-State Fmri Findings For Al001 Accepted For Poster Presentation At Neuroscience 2026	CI

Market Cap	8.24M 7.1M 6.72M 6.09M 11.43M 787M 11.49M 79.85M 30.71M 401M 30.95M 30.27M 1.27B	P/E 2027 *	-1.64x	P/E 2028 *	-1.98x
Enterprise Value	8.24M 7.1M 6.72M 6.09M 11.43M 787M 11.49M 79.85M 30.71M 401M 30.95M 30.27M 1.27B	EV / Sales 2027 *	-	EV / Sales 2028 *	-
Free-Float	97.32%	Yield 2027 *	-	Yield 2028 *	-

09-10	Alzamend Neuro, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2026	CI
08-20	Alzamend Neuro Reports Resting-State Fmri Findings For Al001 Accepted For Poster Presentation At Neuroscience 2026	CI
08-18	Alzamend Neuro, Inc. Reports Phase 1/2A Lithium Imaging Data For AL001 At ISMRM Workshop	CI
08-04	Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending	CI
07-22	Alzamend Neuro, Inc. Reports Earnings Results for the Full Year Ended April 30, 2026	CI
07-21	Alzamend Neuro, Inc. Auditor Raises 'Going Concern' Doubt	CI
07-21	Alzamend Neuro, Inc. Announces Demise of Lynne Fahey Mcgrath, Director on July 20, 2026	CI
04-07	Alzamend Neuro, Inc. Reports Encouraging Pharmacodynamic Data From Phase II Clinical Trial Of AL001	CI
03-26	Alzamend Neuro, Inc. Reports Positive Topline Data From Phase II Clinical Trial of AL001	CI
03-16	Alzamend Neuro Initiates Phase Ii Clinical Trial of Al001 Lithium in Brain Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital	CI
03-16	Alzamend Neuro initiates phase II clinical trial of AL001 "lithium in brain" study in patients with bipolar disorder in collaboration with Massachusetts General Hospital	RE
03-11	Alzamend Neuro, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2026	CI
03-06	Alzamend Neuro Inc enters ATM sales agreement to sell up to $3.0 million in common stock - SEC filing	RE

12/04/23	Maxim Initiates Alzamend Neuro at Buy With $1.50 Price Target	MT
27/12/21	Ascendiant Capital Adjusts Price Target on Alzamend Neuro to $8.25 From $8, Maintains Buy Rating	MT
01/10/21	Alzamend Neuro : Ascendiant Capital Initiates Alzamend Neuro at Buy Rating With $8 Price Target	MT

Alzamend Neuro, Inc. Share Price

Stocks

ALZN

US02262M6057

Biotechnology & Medical Research

Valuation : Alzamend Neuro, Inc.

Chart: Alzamend Neuro, Inc.

Latest news : Alzamend Neuro, Inc.

Analysts' recommendations : Alzamend Neuro, Inc.

Press Releases : Alzamend Neuro, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Alzamend Neuro, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

08-20	Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC	PR
08-18	Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain	PR
07-22	Alzamend Neuro : Annual Report for Fiscal Year Ending April 30, 2026 (Form 10-K)	PU
04-07	Alzamend Neuro : Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital	PU
03-26	Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions	PR

1 day	+1.18%
1 week	+3.61%
Current month	+7.50%
1 month	+17.01%
3 months	+50.22%
6 months	-21.10%
Current year	-5.49%

1 week	1.58	1.76
1 month	1.41	1.76
Current year	0.84	2.54
1 year	0.84	2.68
3 years	0.84	360.31
5 years	0.84	4,819.5
10 years	0.84	45,292.48

Manager	Title	Age	Since
Stephan Jackman CEO	Chief Executive Officer	50	19/11/2018
David Katzoff DFI	Director of Finance/CFO	64	04/08/2022
Henry Nisser LAW	General Counsel	57	30/04/2019

Director	Title	Age	Since
Todd Ault CHM	Chairman	56	25/02/2016
William Horne CHM	Chairman	57	31/05/2021
Stephan Jackman BRD	Director/Board Member	50	31/08/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.	Importance
26/08/26	Todd Ault	Sell	Founder	-2,000	0.0417%
26/08/26	HYPERSCALE DATA, INC.	Other	Company	0	0%	-
31/07/26	HYPERSCALE DATA, INC.	Free	Company	7,500	0.1565%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZAMEND NEURO, INC.	+1.18%	+3.61%	-28.33%	-99.44%	8.15M
LONZA GROUP AG	-0.71%	-6.35%	-4.87%	+9.03%	46.05B
REVOLUTION MEDICINES, INC.	+0.21%	-2.98%	+340.68%	+519.93%	43.59B
IQVIA HOLDINGS INC.	+1.74%	-2.24%	+37.28%	+21.57%	42.35B
BEONE MEDICINES AG	+1.38%	-3.28%	+3.23%	+65.60%	38.86B
CELLTRION, INC.	-1.44%	-5.26%	+8.78%	+36.85%	32.24B
ASCENDIS PHARMA A/S	+0.87%	-2.60%	-	-	17.16B
MEDPACE HOLDINGS, INC.	+0.75%	-0.64%	+18.07%	+110.32%	16.28B
EUROFINS SCIENTIFIC SE	-0.31%	-2.78%	+10.47%	+30.49%	14.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.93%	-3.55%	+74.20%	+39.37%	13.03B
Average	+0.56%	-3.44%	+51.06%	+81.52%	26.39B
Weighted average by Cap.	+0.40%	-4.51%	+73.05%	+123.51%

	2027 *	2028 *
Net sales	-	-
Net income	-10.8M -9.31M -8.81M -7.99M -14.98M -1.03B -15.06M -105M -40.24M -525M -40.56M -39.67M -1.66B	-10.8M -9.31M -8.81M -7.99M -14.98M -1.03B -15.06M -105M -40.24M -525M -40.56M -39.67M -1.66B
Net Debt	-	-

Markets		Quality
Nasdaq	ALZN	Delayed
CBOE	ALZN	Real-time